Forte Biosciences, Inc. (FBRX)
| Market Cap | 1.36B +1,001.6% |
| Revenue (ttm) | n/a |
| Net Income | -75.86M |
| EPS | -4.65 |
| Shares Out | 24.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 108,705 |
| Open | 55.36 |
| Previous Close | 56.63 |
| Day's Range | 54.26 - 57.74 |
| 52-Week Range | 9.10 - 59.56 |
| Beta | 2.84 |
| Analysts | Strong Buy |
| Price Target | 66.60 (+19.63%) |
| Earnings Date | Aug 13, 2026 |
About FBRX
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for FBRX stock is "Strong Buy." The 12-month stock price target is $66.6, which is an increase of 19.63% from the latest price.
News
Forte Biosciences initiated with an Overweight at Barclays
Barclays initiated coverage of Forte Biosciences (FBRX) with an Overweight rating and $74 price target The firm views the company’s CD122 as a “compelling target across multiple immune disorders” give...
Why Is Forte Biosciences (FBRX) Stock Up Today?
Forte Biosciences stock was up on Friday alongside positive results from a clinical trial.
Forte Biosciences trading resumes
09:42 EDT Forte Biosciences (FBRX) trading resumes
Forte Biosciences trading halted, volatility trading pause
09:32 EDT Forte Biosciences (FBRX) trading halted, volatility trading pause
Forte Biosciences Transcript: Study result
A phase I-B, placebo-controlled trial of FB102 in vitiligo showed robust, statistically significant improvements in facial repigmentation, especially in patients with extensive disease, with effects deepening even after treatment cessation. The dual IL-2/IL-15 blockade mechanism yielded favorable efficacy and safety compared to JAK inhibitors, supporting further development.
Forte Biosciences Slides: Study result
Forte Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on July 9, 2026.
Forte Biosciences Press release: Study result
Forte Biosciences issued a press release on July 9, 2026, disclosing material business information to investors.
Forte Biosciences’ FB102 shows efficacy in vitiligo Phase 1b study
Forte Biosciences (FBRX) announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved 29.6% mean FVASI improvement from baseline at week 24; res...
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced ...
Forte Biosciences Registration statement: Registration filing
Forte Biosciences filed a registration statement on June 8, 2026, providing details about a securities offering with the SEC.
Forte Biosciences Registration statement: Registration filing
Forte Biosciences filed a registration statement on June 2, 2026, providing details about a securities offering with the SEC.
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced ...
Forte Biosciences reports Q1 EPS ($1.24), consensus ($1.16)
“FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102’s potential to address the high unmet need in celiac disease. The clinical…
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced ...
Forte Biosciences Quarterly report: Q1 2026
Forte Biosciences has published its Q1 2026 quarterly earnings report on May 11, 2026.
Forte Biosciences Earnings release: Q1 2026
Forte Biosciences released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Forte Biosciences Proxy statement: Proxy filing
Forte Biosciences filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Forte Biosciences 5.71M share Spot Secondary priced at $26.27
The deal size was increased to $150M and priced at the closing price. Guggenheim is acting as sole book running manager for the offering.
Forte Biosciences Announces Pricing of $150 Million Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a publ...
Forte Biosciences announces common stock offering, no amount given
Forte Biosciences (FBRX) announced that it has commenced an underwritten public offering of shares of its common stock. Guggenheim Securities is acting as book-running manager for the offering. Publis...
Forte Biosciences Announces Proposed Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced...
Forte Biosciences reports FY25 EPS ($4.71) vs. ($12.17) last year
“The clinical development for FB102 continues to progress well with important readouts in 2026,” said Forte Biosciences (FBRX) CEO Paul Wagner, PhD. “The topline results from our phase 2 celiac…
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced ...
Forte Biosciences Earnings release: Q4 2025
Forte Biosciences released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Forte Biosciences Annual report: Q4 2025
Forte Biosciences has published its Q4 2025 annual report on March 31, 2026.